ASMB
HealthcareAssembly Biosciences, Inc.
$32.31
$-1.44 (-4.27%)
Jan 5, 2026
Price History (1Y)
Analysis
Assembly Biosciences, Inc. is a healthcare company in the biotechnology industry with a market capitalization of $511.05 million and approximately 73 employees. The company's financial health is characterized by negative profitability metrics, including a gross margin of -66.3%, an operating margin of -100.9%, and a profit margin of -103.6%. Additionally, Assembly Biosciences reported net income of -$38,547,000 and EBITDA of -$43,320,000 in the trailing 12 months. The company's returns on equity and assets are also negative, at -36.9% and -16.0%, respectively. However, Assembly Biosciences has a significant amount of cash on hand, with $232.56 million, while its debt is relatively low at $2.75 million. The valuation context for Assembly Biosciences is marked by a forward P/E ratio of -9.22 and an EV/EBITDA ratio of -7.02. The company's revenue growth rate is 57.6% year-over-year, but earnings growth is not available. There is no dividend yield or payout ratio information available for the company.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Assembly Biosciences, Inc.
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study. The company also develops ABI-7423, an oral broad-spectrum non-nucleoside polymerase inhibitor that targets transplant-related herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Visit website →Key Statistics
- Market Cap
- $511.05M
- P/E Ratio
- N/A
- 52-Week High
- $39.71
- 52-Week Low
- $7.75
- Avg Volume
- 139.71K
- Beta
- 1.15
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 73